Coronary Sinus Reducer an Option for Intractable Angina?
A coronary sinus reducer met one of two primary endpoints by reducing refractory angina in the ORBITA-COSMIC trial, but not the second, improvement in perfusion.
Source: medscape.com
Timothyd Henry News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Timothyd Henry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Timothyd Henry Today - Breaking & Trending Today
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms1GenePHIT is a clinical trial to evaluate the safety and efficacy of the one-time administration of AB-1002 and will include the largest number...
Source: pharmiweb.com
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).
Source: dicardiology.com
AB-1002 Demonstrates Improvements for Congestive Heart Failure in First-in-Human Study
Improvements were seen in left ventricular ejection fraction, NYHA Functional Class, and Minnesota Living with Heart Failure Questionnaire at 1-year post-dose.
Source: pharmacytimes.com
AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions
/PRNewswire/ -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today...
Source: prnewswire.com